CK1 Enzyme May Be New Target for the Treatment of Cancer

Researchers from the New York University (NYU) Cancer Institute, a National Cancer Institute (NCI)-designated cancer center at NYU Langone Medical Center, and collaborators have identified a cell cycle-regulated mechanism behind the transformation of normal cells into cancerous cells. The study shows the significant role that protein networks can play in a cell leading to the development of cancer. The study results, published in the October 21, 2011 issue of the journal Molecular Cell, suggest that inhibition of the CK1 (casein kinase 1) enzyme may be a new therapeutic target for the treatment of cancer cells formed as a result of a malfunction in the cell's mTOR signaling pathway. In the study, NYU Cancer Institute researchers examined certain multi-protein complexes and protein regulators in cancer cells. Researchers identified a major role for the multi-protein complex called SCFβTrCP . This complex assists in the removal from cancer cells of the recently discovered protein DEPTOR, an inhibitor of the mTOR (mammalian Target of Rapamycin) pathway. SCF (Skp1, Cullin1, F-box protein) ubiquitin ligase complexes are responsible for the removal of unnecessary proteins from a cell. This degradation of proteins by the cell's ubiquitin system controls cell growth and prevents malignant cell transformation. Researchers show that inhibiting the ability of SCFβTrCP to degrade DEPTOR in cells can result in blocking the proliferation of cancer cells. In addition, researchers discovered that the activity of CK1, a protein that regulates signaling pathways in most cells, is needed for SCFβTrCP to successfully promote the degradation of DEPTOR. "Low levels of DEPTOR and high levels of mTOR activity are found in many cancers, including cancers of the breast, prostate, and lung," said senior study author Dr.
Login Or Register To Read Full Story